References
Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
Rankin A et al. Oncologist 2016; 21: 1306–1314.
Ross JS et al. Cancer 2016; 122: 2654–2662.
Suh JH et al. Oncologist 2016; 21: 684–691.
Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
FoundationOne®CDx Technical Specifications, 2018. Available at:
FoundationOne®Liquid Technical Specifications, 2018. Available at:
FoundationOne®Heme Technical Specifications, 2017. Available at:
FoundationOne®CDx FDA Approval, 2017. Available at:
FoundationOne®CDx Sample Report, 2018. Available at:
FoundationOne®CDx FDA Approval Press Release, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.htm (Accessed March 2019).
Clark TA et al. J Mol Diagn 2018; 20: 686–702.
Roche Media Release, 2018. Available at:
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.